Aerofact

DRUG2 trials

Sponsors

Aerogen Pharma Limited, Aerogen Pharma

Conditions

Respiratory PaediatricsRespiratory Distress Syndrome in Premature Infant

Phase 2

A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact

CompletedNCT03969992

Aerogen Pharma LimitedRespiratory Distress Syndrome in Premature Infant

Start: 2020-03-04End: 2024-08-05Updated: 2025-08-07

Neonatal Interventional Nebulized Surfactant for Preterm Infants with RDS (Neo-INSPIRe)

RecruitingPACTR202307490670785

Aerogen PharmaRespiratory Paediatrics

Start: 2023-05-14Target: 232Updated: 2026-08-03

Related Papers

A multicentre neonatal interventional randomised controlled trial of nebulized surfactant for preterm infants with respiratory distress: Neo-INSPIRe trial protocol.

2023-09-191 citations